Cisatracurium is a 1R cis-1-prime R cis isomer of atracurium and has a benzylisoquinolinium structure. It is administered intravenously. The typical dose for intubation is 0.15–0.2 mg/kg; ideal intubating conditions are generally achievable after 1.5–2 minutes.
The clinically effective duration of an intubating dose of cisatracurium lasts for about 55 to 65 minutes. The adverse reactions so far reported range less than 1% and include bradycardia, bronchospasm, rash, anaphylaxis, hypotension, prolonged neuromuscular blockade, and myopathy.
